Legend Biotech Corporation
LEGN
Rang in aandelen
#4485
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Aandeelprijs
$18.49
Marktkapitalisatie
$3.42B
Verandering (1 dag)
-2.74%
Verandering (1 jaar)
-43.73%
Land
US
Handel Legend Biotech Corporation (LEGN)
Categorie
Healthcare
Omzet van Legend Biotech Corporation (LEGN)
Omzet in Jun 2026 TTM: $1.27B
Volgens de laatste financiële rapporten van Legend Biotech Corporation bedraagt de huidige omzet van het bedrijf (TTM) $1.27B. In 2023 behaalde het bedrijf een omzet van $285.14M een stijging ten opzichte van de omzet in het jaar 2022, die $117.01M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Legend Biotech Corporation van 2017 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.27B | 102.68% |
| 2024 | $627.24M | 119.97% |
| 2023 | $285.14M | 143.70% |
| 2022 | $117.01M | 70.00% |
| 2021 | $68.83M | -8.23% |
| 2020 | $75.00M | 21.36% |
| 2019 | $61.80M | 25.78% |
| 2018 | $49.13M | 108.24% |
| 2017 | $23.59M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 893.02% |
US
|
|
| $2.23B | 75.25% |
US
|
|
| $15.74B | 1,138.44% |
AU
|
|
| $6.02B | 373.63% |
NL
|
|
| - | - |
CH
|
